Ortho-Clinical Diagnostics, Inc. Receives CE Mark for VITROS® Chemistry Products HbA1c Reagent Kit, an Enhanced Diabetes Testing Assay
Ortho-Clinical Diagnostics, Inc. today announced that it obtained CE Mark (Conformité Européenne) for the VITROS® Chemistry Products HbA1c Reagent Kit, an enhanced assay to detect and monitor blood glucose levels over time in diabetes patients. The assay determines the percentage of glycated hemoglobin (HbA1c) in human whole blood. It is to be used as an aid in the diagnosis of diabetes and as an aid in identifying patients who may be at risk for developing diabetes. Measurements are effective in monitoring long-term glucose control in individuals with diabetes. The product will be available in the European Economic Area and several other countries in November 2014.
Using patented VITROS® MicroTip Technology, the new assay runs on the Ortho Clinical Diagnostics VITROS® Chemistry and Integrated systems and provides operational, performance and clinical improvements compared to the company’s existing assay. The improved VITROS® Chemistry Products HbA1c assay can be used to aid in the diagnosis and identification of patients at risk for developing diabetes. It also offers higher throughput, simplified calibration and improved accuracy to meet the recently tightened National Glycohemoglobin Standardization Program (NGSP) certification requirements. The purpose of the NGSP is to standardize HbA1c test results to those of the Diabetes Control and Complications Trial (DCCT)1 and United Kingdom Prospective Diabetes Study (UKPDS)2, which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes.
The percent of glycated hemoglobin (HbA1c) in a person’s blood is the worldwide standard for measuring blood glucose levels to detect and monitor diabetes. According to the World Health Organization, 347 million people around the globe have diabetes. The disease, a leading cause of blindness, amputation and kidney failure, is predicted to become the seventh leading cause of death in the world by the year 2030.3
“Ortho Clinical Diagnostics is demonstrating our deep commitment to meet the challenges of today’s lab professional by continuing our investment in bringing new and enhanced products like the VITROS® Chemistry Products HbA1c assay to market,” said Robert Yates, Chief Operating Officer, Ortho Clinical Diagnostics. “This new assay will enable our customers to more effectively and productively diagnose and monitor diabetes as the rate of the disease continues to climb around the world.”
The new VITROS® Chemistry Products HbA1c Kit can run on three different VITROS® platforms: the 5,1 FS Chemistry System, the 4600 Chemistry System and the 5600 Integrated System. The assay uses VITROS® MicroTip Technology, which offers a special chemistry menu and user-defined assays in a cost-effective, easily implemented format. It utilizes single-use disposable tips and closed reagent packs to eliminate the risk of sample carryover, reagent-to-reagent contamination and extend on-board reagent stability. Similar to VITROS® MicroSlide and MicroWell Technologies, this is performed without the need for water.
About VITROS ® Systems
Ortho Clinical Diagnostics pioneered the VITROS® series of systems in 1978 and continues to expand and evolve these sophisticated laboratory systems to reduce the probability of human error, improve operational efficiencies and increase uptime in clinical labs. The VITROS® series of systems includes automated, integrated and compact analyzers that offer immunoassay and chemistry detection with standardized reagents and results across all platforms. The introduction of the exclusive VITROS® MicroSlide Technology revolutionized chemistry and immunoassay testing by offering the first and only dry slide technology, eliminating the need for a water supply. VITROS® MicroSlide Technology is one of the five enabling technologies, which also include VITROS® MicroTip Technology, VITROS® MicroWell Technology, VITROS® MicroSensor Technology and VITROS® IntelliCheck® Technology. These technologies power the transformational performance in labs around the world by delivering confidence in results, productivity and financial predictability as well as environmental benefits.
In addition, the Ortho Clinical Diagnostics broad menu of more than 125 VITROS® assays offers all of the most important clinical chemistry tests, covering major disease states including heart disease, cancer, endocrine disease, infectious disease, thyroid disease, metabolic conditions and anemia.
About Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc. delivers high-quality in vitro diagnostic products that give healthcare professionals around the world the knowledge they need to make better treatment decisions sooner. The company serves the global transfusion medicine community with donor screening and blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit. Ortho Clinical Diagnostics also brings sophisticated information management, testing technologies and automation and interpretation tools to clinical laboratories worldwide to help them run more efficiently and improve patient care. For more information, visit .
The VITROS® Chemistry Products HbA1c Reagent Kit, VITROS® 5,1 FS, VITROS® 4600, VITROS® 5600, VITROS® MicroSlide, VITROS® MicroTip, VITROS® MicroWell, VITROS® MicroSensor, VITROS® IntelliCheck® and the VITROS® logo are trademarks of Ortho-Clinical Diagnostics, Inc.
1 The Diabetes Control and Complications Trial Research
Group. The effect of intensive treatment of diabetes on the development
and progression of long-term complications in insulin-dependent diabetes
mellitus. N Engl J Med. 1993; 329 (14): 977–86.
2
King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study
(UKPDS): Clinical and therapeutic implications for type 2 diabetes. Br
J Clin Pharmacol. 1999; 48(5):643-648.
3 World
Health Organization. Diabetes fact sheet (October 2013). Available at:
Accessed September 19, 2014.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact information
Ortho-Clinical Diagnostics, Inc.
Stephanie Scott,
908-218-8137
Cell: 908-720-6859
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo